Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.78 |
| ▸ | HTR7 | P34969 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011780 | 0.89 | HTR1A (0.73) | HTR1AHTR7ALDH1A1DRD2DRD4 | |
| SCHEMBL6352028 | 0.88 | HTR1A (1.00) | HTR1AALDH1A1MAPTHTTKMT2A | |
| SCHEMBL11045002 | 0.85 | HTR1A (0.68) | HTR1AHTR7ALDH1A1KMT2ADRD2 | |
| SCHEMBL11630844 | 0.84 | HTR1A (0.67) | HTR1AHTR7ALDH1A1KMT2ADRD2 | |
| SCHEMBL6358631 | 0.83 | DRD4 (0.66) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL6358629 | 0.83 | DRD4 (0.66) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL6360188 | 0.81 | DRD4 (0.84) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL6360190 | 0.81 | DRD4 (0.84) | HTR1AHTR7DRD2DRD4DRD3 | |
| SCHEMBL9293656 | 0.80 | DRD2 (0.66) | HTR1AHTR7ALDH1A1HTTKMT2A | |
| SCHEMBL11759007 | 0.80 | ALDH1A1 (0.87) | HTR1AALDH1A1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | HTR1A 871/4885HTR7 642/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.